Pfizer’s conditional Braftovi combination therapy shows that the response of patients with colorectal cancer is improved-NYSE: PFE)

Saturday, Pfizer PFE The results of the third -stage warehousing test were revealed, the trial evaluated the BRAFTOVI (ENCORAFENIB) and Cetuximab (sales with ERBITUX) and MFOLFOX6 (fluorinerine, white cellin and Oxaliptin) combined with metastatic colorectal cancer (MCRC) and A. Braf V600E mutation.

In the analysis, compared with patients who accept or have no chemotherapy of Bervar Midam, the clinical significance and statistical increase in the clinical significance and statistical improvement of the confirmed objective response (ORR) shows (60.9 %, 40.0 % To.

Please also read: In the patented cliff challenge, Pfizer’s eyes received a $ 20 billion income from the acquisition

Results were introduced in the Gastrointestinal Cancer Symposium (ASCO GI) of the American Clinical Oncology Society of Clinical Oncology in 2025, and published it at the same time Natural medicineEssence

BRAFTOVI plus the estimated response duration of Siciecci Ming and MFOLFOX6 and 11.1 months is 13.9 months, and chemotherapy with or without Belidab is 11.1 months.

Among the patients with Braftovi Plus Cetuximab and MFOLFOX6, 22.4 % (n = 15) reacted for 12 months or longer, and 11.4 % (n = 5) with or without Belid monetary resistance.

BRAFTOVI plus the median reaction time of Sicieccumab and MFOLFOX6 and 7.3 weeks is 7.1 weeks, and chemotherapy using or not using Berandab.

In this analysis process, the overall survival rate (OS) data is immature, but compared with patients with chemotherapy or Barvar’s chemotherapy, it is conducive to the trend of Braftovi Plus Cetuximab and MFOLFOX6.

The median overall survival period of BRAFTOVI and Cetuximab and chemotherapy is inestimable, and chemotherapy with Barvar Monopsis is 14.6 months.

The dyke trial is undergoing OS and no progressive survival (PFS), and PFS results are expected to be carried out in 2025.

The security overview of BRAFTOVI and Sicien Ming and MFOLFOX6 in the warehouse test are consistent with the known safety overview of their respective agents. No new security signals were found.

In December 2024, FDA and Cetuximab and MFOLFOX6 jointly obtained the acceleration approval of BraftoviRoyal Air Force V600E-MCRC.

Price action: On Monday’s last check, PFE stocks rose 2.76 % to $ 26.81.

Read the next post:

Through shutterstock image